Cynthia M Richards

US Patent:

6337209, Jan 8, 2002

Filed:

Nov 19, 1993

Appl. No.:

08/154712

Inventors:

Brian Huber - Durham NC
Cynthia A. Richards - Durham NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

C12N 510

US Classification:

435325, 435363, 435366, 4353201, 536 231, 536 232, 536 235, 536 237, 536 241

Abstract:

Novel molecular chimaeras produced by recombinant DNA techniques are described. They comprise a target-tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase (VZV TK) or non-mammaliam Cytosine Deaminase(CD). A molecular chimaera is packaged into a synthetic retroviral particle that is capable of infecting mammalian tissue. This, in turn, may be administered to a host, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous cells). Administration of compounds that are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cells.

US Patent:

6699690, Mar 2, 2004

Filed:

Sep 6, 2001

Appl. No.:

09/947925

Inventors:

Brian Huber - Durham NC
Cynthia A. Richards - Durham NC

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

C12N 510

US Classification:

435 691, 4353201, 435325, 435455, 435456, 435457, 435183, 435194, 435230, 536 231, 536 232, 536 235, 536 237, 536 2374, 536 241, 424 931, 424 932, 424 936

Abstract:

Novel molecular chimaeras produced by recombinant DNA techniques are described. They comprise a target-tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase (VZV TK) or non-mammaliam Cytosine Deaminase (CD). A molecular chimaera is packaged into a synthetic retroviral particle that is capable of infecting mammalian tissue. This, in turn, may be administered to a host, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous cells). Administration of compounds that are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cells.

US Patent:

20020042137, Apr 11, 2002

Filed:

Jul 11, 2001

Appl. No.:

09/903452

Inventors:

Cynthia Richards - Durham NC, US
Michael Weiner - Cary NC, US

International Classification:

C12N015/861
C07H021/04
C12N007/01

US Classification:

435/456000, 435/235100, 536/023720

Abstract:

The present invention provides a system for simple generation of recombinant animal viruses. The system includes a virus homing vector and can further comprise a transfer vector. These components are used in a system that reduces the number of cloning steps and provides for easier preparation of a number of recombinant viruses.

US Patent:

62912143, Sep 18, 2001

Filed:

May 10, 1999

Appl. No.:

9/309382

Inventors:

Cynthia Ann Richards - Durham NC
Michael Phillip Weiner - Cary NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

C12N 1564
C12N 502
C12N 1563
C12N 121
C12N 119

US Classification:

435 914

Abstract:

The present invention provides a system for simple generation of recombinant animal viruses. The system includes a virus homing vector and can further comprise a transfer vector. These components are used in a system that reduces the number of cloning steps and provides for easier preparation of a number of recombinant viruses.

US Patent:

63004909, Oct 9, 2001

Filed:

Jun 7, 1995

Appl. No.:

8/481968

Inventors:

Brian Huber - Durham NC
Cynthia A. Richards - Durham NC
Elizabeth A. Austin - Raleigh NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

C07H 2104
C12N 1585

US Classification:

536 237

Abstract:

Novel molecular chimaeras produced by recombinant DNA techniques are described. They comprise a target-tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase (VZV TK) or non-mammaliam Cytosine Deaminase(CD). A molecular chimaera is packaged into a synthetic retroviral particle that is capable of infecting mammalian tissue. This, in turn, may be administered to a host, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous cells). Administration of compounds that are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cells.

US Patent:

61942111, Feb 27, 2001

Filed:

May 16, 1996

Appl. No.:

8/646301

Inventors:

Cynthia Ann Richards - Durham NC
Brian Huber - Durham NC

Assignee:

Glaxo Wellcome Inc. - Research Triangle Park NC

International Classification:

C12N 1563
C12N 15867
C12N 510
C07H 2104

US Classification:

435456

Abstract:

The transcriptional regulatory sequence (TRS) of Carcinoembryonic Antigen (CEA) and molecular chimeras comprising the CEA TRS and DNA encoding a heterologous enzyme are described. Such molecular chimeras are capable of targeting the expression of the heterologous enzyme to CEA-positive cells. The heterologous enzyme may be cytosine deaminase.